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Edward D. Ball1Autologous peripheral blood stem/progenitor cell transplantation (APBSCT) has been investigated as a
potential therapeutic option to improve outcome in patients with acute myelogenous leukemia (AML). How-
ever, its optimal role in treatment for adults in remission has not been clearly established. We performed
a retrospective analysis on 45 patients aged 21 to 73 years (median 51 years) with de novo AML who under-
went APBSCT stratified by age, complete remission status, and cytogenetic risk. The 5-year disease-free sur-
vival (DFS) for all patients was 33.9% (95% confidence interval [CI], 20.1%-53.7%) and overall survival (OS)
was 43.6% (CI, 29.2%-62.8%). For patients under the age of 60 years, the 5-year DFS for intermediate and
high cytogenetic risk was 53.3% (CI, 23.5%-85.6%) and 50.0% (CI, 16.1%–100.0%); the 5-year OS for patients
under the age of 60 years with low, intermediate, and high cytogenetic risk was 80.0% (CI, 40.0%-100.0%),
60.0% (CI, 31.2%-90.7%), and 75.0% (CI, 39.0%-100.0%), respectively. For patients over the age of 60 years,
the 5-year DFS and OS for intermediate cytogenetic risk was 21.4% (CI, 7.9%-58.4%) and 21.4% (CI, 7.9%-
58.4%). The DFS and OS of these patients are comparable to the historic survival of those who underwent
allogeneic stem cell transplantation when adjusted by age. In addition, there was no treatment-related
mortality (TRM). We conclude that APBSCT is a reasonable and safe intensive consolidation for patients
with AML who do not have a suitable HLA-matched donor.
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Once thought to be a single disease, acute
myelogenous leukemia (AML) represents a heteroge-
neous group of clonal hematopoietic stem cell (HSC)
disorders. The result of uncontrolled proliferation of
the abnormal clonal population is that of impaired nor-
mal hematopoiesis. Left untreated, patients ultimately
die from infectious or bleeding complications as se-
quelae of their compromised BM.1Department of Medicine, 2Pathology, 3Biostatistics,
rsity of California, San Diego, La Jolla, California.
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6/j.bbmt.2009.06.006The overall incidence of AML is 3.4 cases per
100,000 population, with increasing incidence as age
increases [1]. Approximately 50% to 75% of adults
with AML achieve complete remission (CR) with
induction chemotherapy, only to have 20% to 30% of
patients enjoy long-term disease-free survival (DFS)
[2]. Although there have been advances in the under-
standing of the pathophysiology of AML, these have
yet to lead to any major improvements in long-term
survival of adults with this disease in the last 2 decades.
Allogeneic BM transplant (BMT) as a consolida-
tion therapy has been shown to significantly reduce
the relapse rate, albeit with considerable treatment re-
lated mortality [3]. In consideration of the above, se-
lection of the optimal therapy for an individual
patient has been risk stratified based on the cytogenetic
phenotype of the malignant cells. Patients who have
low-risk cytogenetics and who attain a CR after induc-
tion chemotherapy are typically treated with 3 to 4 cy-
cles of high-dose consolidation chemotherapy,
whereas for those of intermediate- and high-risk cyto-
genetics and who have an available histocompatible
Biol Blood Marrow Transplant 15:1306-1313, 2009 1307Autologous HSCTas an Intensive Therapy for Patients with AMLdonor, allogeneic BMT has become a standard option
for consolidation. A major limitation of allogeneic
BMT has been that it can only be considered in a mi-
nority of patients because of difficulties in identifying
a suitable donor and/or the age and comorbidities of
the patients. The process of allogeneic transplant
also carries significant morbidity and mortality. Fur-
thermore, the optimal consolidation therapy for the
intermediate- to high-risk AML patients who are in re-
mission without a potential histocompatible donor has
yet to be clearly established.
Autologous peripheral blood stem/progenitor cell
transplantation (APBSCT) has also been investigated
as a potential therapeutic option to improve outcome
in selected patients with AML. APBSCT compares fa-
vorably against allogeneic BMT in several ways.
APBSCT can be used as a consolidation therapy in
the older population, and lack of a matched donor
does not preclude the patients from this treatment
[4]. Autologous BMT also avoids the complications
of graft-versus-host disease (GVHD), and it is associ-
ated with fewer life-threatening infections, both of
which are significant contributors to morbidity and
mortality in allogeneic BMT. A considerable body of
clinical experience has been reported describing the
results of APBSCT using both BM and mobilized
PBSCs, a variety of mobilization and preparative regi-
mens, overall treatment strategies, cell sources,
methods of graft engineering, and other variables. De-
spite the knowledge gained from these trials, there is
no consensus regarding the precise role of APBSCT
in AML treatment.
Here, we report a retrospective analysis on 45 pa-
tients diagnosed with de novo AML, who did not have
an availablehistocompatible donor, andwhounderwent
APBSCTbetween the years 2000 and 2007 at our insti-
tution using a variation on a previously reported stem
cellmobilization strategy [5] and afixedpreparative reg-
imen of i.v. busulfan (Bu) and cyclophosphamide (Cy).
Three patients received melphalan (Mel) in lieu of Cy
in the preparative regimen. We report that, using the
methods described, the clinical results of APBSCT are
sufficiently encouraging to warrant future trials that in-
clude APBSCT as an option for appropriately selected
patients with AML in CR1 or CR2.PATIENTS AND METHODS
Patients
All patients, initially diagnosed with de novo AML
who underwent APBSCT between the years 2000 and
2007 at our institution are included in the analysis. All
patients had an ECOG score of 1 or less, and none had
an available histocompatible donor at the time of
transplantation. The patients’ age ranged from 21 to
73 years, with a median age of 51 years. There were23 females and 22 males. Details of the patients’ clini-
cal characteristics are provided in Table 1.
CR was confirmed by BMmorphology and immu-
nophenotype analysis by flow cytometry prior to har-
vesting of stem cells and subsequent transplantation.
Thirty-nine patients were in their first complete re-
mission (CR1), and 6 patients were in their second
complete remission (CR2) at the time of transplant.
Patients in remission had undergone consolidation
therapy with variable numbers of cycles of high dose
ARA-C chemotherapy prior to stem cell mobilizaton
and transplantation. Definitions of CR and
engraftment are consistent with International AML
Working Group recommendations [6].
All patients had left ventricular ejection fraction
(LVEF) .50%, carbon dioxide diffusion capacity
(DLCO) of .60%, or forced expiratory volume
(FEV).75% predicted as well as adequate renal func-
tion as determined by serum creatinine\2 times nor-
mal and adequate liver function as determined by
bilirubin, serum glutamic oxaloacetic transaminase
(SGOT) (aspartate aminotransferase [AST]), and alka-
line phosphatase\3 times normal.
TheFrenchAmericanBritish (FAB) classificationof
the patients were as follows: M1, 3; M2, 13; M3, 2; M4,
9; M5, 13; M6, 2; unknown, 2; not otherwise specified
(NOS), 1. Cytogenetic analysis was available on 41 of
the 45 patients. Of these, 26 had a normal karyotype, 1
had inversion 16, 1 had inversion 16 and 18 and 122,
1 had t(15;17), 3 had t(8;21), 1 each had – Y, t(11;19),
t(9;22), t(6;7), 16 del 20, t(9;11), 18 and 19, del 9,
28, and del 10, and 216 and 217, and 218 and 219,
and 13. Recognizing that numerous cytogenetic risk
stratification systems exist, some of which include
t(9;22) in the high-risk category, the results of our pa-
tients’ cytogenetic analysis were then stratified to low,
intermediate, or high risk based on cytogenetic pattern
observed by Grimwade et al. [7]. FLT-3 and nucleo-
phosmin mutations were not routinely performed on
these patients and are therefore not available.Stem/Progenitor Cell Collection and Processing
For stemcellmobilization,wemodifiedapreviously
reported regimen that was used with success in patients
with AML [5]. Patients received high-dose cytarabine
(2000 mg/m2) and etoposide (5 mg/kg) for 3 days fol-
lowed by granulocyte colony-stimulating factor (G-
CSF) at 10 mg/kg, starting 10 days after the above che-
motherapy. Patients underwent PBSC collection via
apheresis when the leukocyte count had increased to
10,000 per microliter, as described [8]. Six patients re-
quired remobilization, using G-CSF to collect suffi-
cient CD34 cells for transplant. HPC were collected
using the AutoPBPC program employing a COBE
Spectra instrument, and20Lof bloodwas typically pro-
cessed at each session. The cells were volume reduced
Table 1. Clinical Characteristics of Patients
UPN FAB
Cytogenetics
of Diagnosis
Cytogentic
Risk
Age at
BMT (Yrs)
Induction
Therapy
Prep
Reg.
CR Status
Pre APBSCT
Days
To PD
Current
Status
Days To
Death
1 M6 normal female intermediate 68 FLAG Bu/Cy CR 1 368 DEAD 388
2 M4 normal female intermediate 39 Ida and Ara-C Bu/Cy CR 1 ALIVE
3 M2 45X,-Y(3)/46,XY(cp16),
trisomy 8
intermediate 61 FLAG Bu/Cy CR 1 824 DEAD 843
4 M5 normal female intermediate 33 Ida and Ara-C Bu/Cy CR 1 50 DEAD 56
5 M5 normal female intermediate 66 Ida and Ara-C Bu/Cy CR 1 ALIVE
6 M2 normal female intermediate 68 Ida and Ara-C Bu/Cy CR 1 ALIVE
7 M5 normal female intermediate 69 Mitoxantone and Ara-C Bu/Cy CR 1 ALIVE
8 M2 46XX,del(19) t(11;19)
(q13,q13)
high 21 Ida and Ara-C Bu/Cy CR 2 162 ALIVE
9 M2 46XX,t(9;22) (q34;q11.2) high 58 Ida and Ara-C Bu/Cy CR 1 35 DEAD 248
10 M2 46XY,t(8;21), del(9) low 38 Ida and Ara-C Bu/Cy CR 1 204 ALIVE
11 M1 normal male intermediate 41 Ida,Ara-C and Mylotarg Bu/Cy CR 1 ALIVE
12 M4 t(6;7) (p23;q38) intermediate 73 FLAG Bu/Cy CR 1 97 DEAD 106
13 Unk 47XY,+6,del(20)(q13.1)
[cp15]/6XY[5]
high 72 FLAG Bu/Cy CR 1 DEAD 641
14 M5 Not available Not available 42 Ida and Ara-C Bu/Cy CR 1 89 DEAD 177
15 M5 t(9;11), abnormal 11q23,+8 high 23 Ida and Ara-C Bu/Cy CR 1 ALIVE
16 M5 trisomy 8 and 9 high 31 Ida and Ara-C Bu/Cy CR 1 ALIVE
17 M2 46XX del(9) (q12q22)[18] intermediate 31 Ida and Ara-C Bu/Cy CR 1 167 ALIVE
18 M1 Not available Not available 64 Ida and Ara-C Bu/Cy CR 1 465 DEAD 595
19 M5 normal female intermediate 32 Ida and Ara-C Bu/Cy CR 1 61 DEAD 261
20 M2 normal female intermediate 61 Ida and Ara-C Bu/Mel CR 1 205 DEAD 387
21 M2 normal male intermediate 64 Ida and Ara-C Bu/Cy CR 1 DEAD 555
22 M4 complex* high 65 FLAG Bu/Mel CR 1 190 DEAD 291
23 Unk normal male intermediate 65 FLAG Bu/Cy CR 1 DEAD 1581
24 M3 translocation low 39 Ida and Ara-C with ATRA Bu/Cy CR 2 ALIVE
25 M4 normal female intermediate 50 Ida and Ara-C Bu/Cy CR 1 ALIVE
26 M2 normal male intermediate 19 Ida and Ara-C Bu/Cy CR 1 ALIVE
27 M4 normal male intermediate 69 Ida and Ara-C;FLAG;
FLAG and Ida
Bu/Cy CR 2 89 DEAD 137
28 M6 Not available Not available 54 Ida and Ara-C Bu/Cy CR 1 ALIVE
29 M3 Not available Not available 23 DNR,ARA-C and ATRA Bu/Cy CR 2 1038 ALIVE
30 M2 normal female intermediate 62 Ida and Ara-C Bu/Cy CR 1 80 DEAD 371
31 M5 normal male intermediate 36 Ida and Ara-C Bu/Cy CR 1 ALIVE
32 M2 45,X,-Y,t(8;21)
(q22;q22)[20]
low 42 Ida and Ara-C Bu/Mel CR 2 113 DEAD 144
33 M5 normal male intermediate 69 Anthracycline and Ara-C Bu/Cy CR 1 21 DEAD 267
34 M5 normal female intermediate 50 Ida and Ara-C Bu/Cy CR 1 ALIVE
35 M5 normal male intermediate 51 Ida and Ara-C;FLAG Bu/Cy CR 2 160 DEAD 288
36 M5 normal female intermediate 31 Anthracycline and Ara-C Bu/Cy CR 1 87 DEAD 223
37 M2 t(8;21) translocation low 40 DNR and Ara-C Bu/Cy CR 1 ALIVE
38 M2 normal male intermediate 58 FLAG Bu/Cy CR 1 DEAD 167
39 M1 normal female intermediate 25 DNR and Ara-C Bu/Cy CR 1 ALIVE
40 M4 normal female intermediate 55 Ida and Ara-C Bu/Cy CR 1 ALIVE
41 M4 normal male intermediate 67 FLAG Bu/Cy CR 1 83 DEAD 391
42 NOS normal male intermediate 58 Ida and Ara-C;FLAG Bu/Cy CR 1 256 DEAD 408
43 M5 normal female intermediate 61 Ida and Ara-C Bu/Cy CR 1 81 DEAD 145
44 M4 inversion
chromosome 16
low 27 Ida and Ara-C Bu/Cy CR 1 ALIVE
45 M4 inversion 16,
trisomy 8, trisomy 22
low 49 Ida and Ara-C Bu/Cy CR 1 ALIVE
UPN indicates unique patient number; FAB, French-American-British system; Unk, unknown; NOS, not otherwise specified; *42,X,-Y,-5,add(7)(p14), -8,
-del(10)(q22),add(11)(q23),add(12)(p12),-16,-17,-18-19, +3mar[cp16]46,XY[3]; FLAG, fludarabine, cytarabine and granulocyte-colony stimulating fac-
tor; Ida, idarubicin; ARA-C, cytarabine; ATRA, all-trans retinoic acid; DNR, daunorubicin; Bu, busulfan; Cy, cyclophosphamide; Mel, melphalan; APBSCT,
Autologous peripheral blood stem/progenitor to cell transplantation; BMT, bone marrow transplantation; PD, progressive disease; CR, complete remis-
sion.
1308 Biol Blood Marrow Transplant 15:1306-1313, 2009A. S. Jung et al.and cryopreserved in 10% DMSO with 10% autolo-
gous plasma using a controlled rate freezer and stored
until transplant in the vapor phase of liquid nitrogen.
CD341 cells were analyzed in duplicate using a dual
platform method according to ISHAGE guidelines
[9]. Cells were then thawed rapidly in a 37C water
bath at the bedside on the day of infusion and infused
within 10 minutes.Preparative Chemotherapy and Stem Cell
Transplantation
The preparative chemotherapy regimen prior
to autologous transplantation with cryopreserved
stem/progenitor cells consisted of a combination of
i.v. Bu (0.8 mg/kg for 16 doses) and Cy (60 mg/kg for
2 doses) for 42 patients. Bu and Mel regimen was
used for the remaining 3 patients. The chemotherapy
Biol Blood Marrow Transplant 15:1306-1313, 2009 1309Autologous HSCTas an Intensive Therapy for Patients with AMLwas dosed based either on actual or ideal body weights,
whichever was lower. For patients 25% or more above
their ideal body weight, an adjusted weight was used,
which added 25% of the difference between the ad-
justed and ideal weight to the ideal weight. The stem/
progenitor cells were infused on day 0. The median
number of cells infused was 4.95  106 CD341 cells/
kg of adjusted body weight with a range of 0.92 to
16.77  106 CD341 cells/kg cells.
Supportive Care
All patients were hospitalized in private rooms.
Oral acyclovir 400 mg orally administered twice a day
and itraconazole 400 mg orally daily were begun on
day 11 and continued for at least 100 days after
transplant. A broad-spectrum antibiotic, usually
ciprofloxacin 500 mg orally twice a day, was used pro-
phylactically during periods of neutropenia, defined as
neutrophil count \1000/mL. Other antibiotics were
used as needed for treatment of suspected or proven
infections.Plateletswere transfused tomaintain aplate-
let count .10,000/mL or a higher threshold if there
were any signs of bleeding. Red blood cells (RBCs)
were transfused to maintain a hematocrit .24%.
Treatment-Related Mortality (TRM)
TRM was defined as death of a patient resulting
from a direct consequence during the APBSCT pro-
cess, from the time of collection of stem cells to the
time of stem cell engraftment.
Statistical Measures
Kaplan-Meier estimates were calculated for over-
all survival (OS) and progression-free survival (PFS)
from the date of APBSCT; 5-year survival rates and
their confidence intervals (CIs) were also computed.
The computations were stratified by age, cytogenetics
risk, and remission status at transplant. No estimates
were provided if all the subjects in a subgroup dropped
out of the study prior to 5 years because of any reason.
Survival distributions between groups were compared
using a log-rank test. Data were frozen as of December
19, 2008. All analyses used the statistical package R
version 2.5.1, 2007 (www.r-project.org).Figure 1. DFS for all patients.RESULTS
Engraftment
For patients in CR1, a median cell count of 5.13 
106 CD341 cells/kg body weight (range: 1.34-16.77 
106 CD341 cells/kg body weight) was infused on the
day of transplantation. For patients in CR2, a median
of 3.29  106 CD341 cells/kg body weight (range:
0.96-9.45  106 CD341 cells/kg body weight) was
infused.The speed of neutrophil and platelet recovery was
observed. The median time for neutrophil recovery to
absolute neutrophil count of .500 cells/mL was 12
days (range: 10-21 days). The median time for platelet
recovery to platelet count of .20,000/mL and of
.50,000/mL without transfusion dependency was
13 days (range: 0-35 days) and 17 days (range:
11-214 days), respectively.
The average infused CD341 cell dose for patients
who remained in continuous CR versus those who re-
lapsed was 5.8 versus 5.4  106 CD341 cells/kg body
weight. Neither the dose of cells infused nor the num-
bers of cellsmobilizedwas predictive of time to relapse.
TRM
No TRM was observed during the APBSCT.
Disease-Free Survival (DFS) and OS
DFS and OS of the patients are shown in Figures 1
and 2. The DFS and OS are presented overall and also
stratified by cytogenetic risk, age, and remission status
at time of transplant (CR1 and CR2). The 5-year DFS
of the 45 patients who underwent APBSCTwas 33.9%
(95% CI, 20.1%-53.7%). The 5-year OS was 43.6%
(CI, 29.2%-62.8%). Six patients whose disease pro-
gressed subsequently underwent allogeneic transplan-
tation, 2 of whom are alive and 4 of whom died from
progressive disease despite the allogeneic transplanta-
tion. The DSF and OS of the patients stratified by the
above subgroups are shown in Table 2.
Cytogenetic Risk
For patients with intermediate (n 5 29), and high
(n 5 6) cytogenetic risks, the 5-year DFS rates were
34.6% (CI, 19.2%-59.6%), and 25.0% (CI, 5.0%-
100.0%) respectively. The 5-year OS rates for the 3
cytogenetic risks (low [n 5 6], intermediate [n 5 29],
Figure 2. OS for all patients.
1310 Biol Blood Marrow Transplant 15:1306-1313, 2009A. S. Jung et al.and high [n 5 6]) were 80% (CI, 40.0%-100.0%),
38.4% (CI, 22.6%-63.0%), and 44.4%, respectively
(CI, 16.7%-100.0%). Those with unknown cytogenet-
ics were excluded.
Age
The 5-year DFS rates for patients under the age of
60 and for those $60 were 49.6% (CI, 26.9%-74.5%)
and 17.6% (CI, 6.3%-49.3%). The 5-year OS rates for
the above groups were 65.9% (CI, 43.3%-86.9%) and
17.6% (CI, 6.3%-49.3%).
CR1/CR2
For patients in CR1 who underwent APBSCT, the
5-year DFS was 37.0% (CI, 22.3%-59.3%). One of 6Table 2. Disease-Free and Overall Survival of AML Patients Stratifi
Disease-Fre
Age #59 years (n 5 28) 49.6% (CI, 2
$60 years (n 5 17) 17.6% (CI, 6
CR status CR1 (n 5 39) 37.0% (CI, 2
CR2 (n 5 6) N/A†
Cytogenetic risk‡
Low (n 5 6) N/A†
Intermediate (n 5 29) 34.6% (CI, 1
High (n 5 6) 25.0% (CI, 5
Cytogenetic risk‡ for age #59 years
Low (n 5 6) N/A†
Intermediate (n 5 15) 53.3% (CI, 2
High (n 5 4) 50.0% (CI, 1
Cytogenetic risk‡ for age $60 years
Low (n 5 0) N/A†
Intermediate (n 5 14) 21.4% (CI, 7
High (n 5 2) N/A†
Combined (n 5 45) 33.9% (CI, 2
CR indicates complete remission; AML, acute myelogenous leukemia; N/A, no
*Survival rates are at 5 years.
†N/A indicates no available subjects for analysis that met 5-year requirement.
‡Unknowns were excluded from analysis.patients in CR2 was disease-free after 4 years of fol-
low-up, and the remainder had progressed by this
time. The 5-year OS in CR1 (n 5 39) and CR2 (n 5
6) was 42.1% (CI, 27.3%-63.6%) and 50.0% (CI,
16.1%-100.0%), respectively.
Cytogenetics with Age
For patients under the age of 60 years, the 5-year
DFS rates based upon intermediate (n 5 15) and
high (n 5 4) risks were 53.3% (CI, 23.5%-85.6%)
and 50.0% (CI, 15.1%-100.0%), respectively (Fig-
ure 3). The OS for low (n 5 6), intermediate (n 5
15), and high (n 5 4) risks were 80.0% (CI, 40.0%-
100.6%), 60.0% (CI, 31.2%-90.7%), and 75.0% (CI,
39.0%-100.0%), respectively (Figure 4).
For patients over the age of 60, the 5-year DFS
rates based upon intermediate (n 5 14) risks were
21.4% (CI, 7.9%-58.4%) (Figure 5). The 5-year OS
was 21.4% (CI, 7.9%-58.4%) (Figure 6). Those with
unknown cytogenetics were again excluded.DISCUSSION
Despite advances in our understanding of its path-
ogenesis, AML remains difficult to treat. Although ini-
tial CR can be achieved in a high percentage of
patients, relapse occurs in 70% to 80% of the patients.
Various approaches of consolidating the remission
state have been attempted. The 2 main approaches
have been the attempt to eradicate the leukemic clonal
cell population via chemotherapy (with or without au-
tologous stem cell rescue) or to pursue a combined ap-
proach using an antileukemic therapy combined with
an antileukemic immune response via allogeneic
bone marrow transplantation.ed by Age and Cytogenetic Risk
e Survival*(DFS) Overall Survival*(OS)
6.9%-74.5%) 65.9% (CI, 43.3%-86.9%)
.3%-49.3%) 17.6% (CI, 6.3%-49.3%)
2.3%-59.3%) 42.1% (CI, 27.3%-63.6%)
50.0% (CI, 16.1%-100.0%)
80.0% (CI, 40.0%-100.0%)
9.2%-59.6%) 38.4% (CI, 22.6%-63.0%)
.0%-100.0%) 44.4% (CI, 16.7%-100.0%)
80.0% (CI, 40.0%-100.0%)
3.5%-85.6%) 60.0% (CI, 31.2%-90.7%)
5.1%-100.0%) 75.0% (CI, 39.0%-100.0%)
N/A†
.9%-58.4%) 21.4% (CI, 7.9%-58.4%)
N/A†
0.1%-53.7%) 43.6% (CI, 29.2%-62.8%)
t applicable.
Figure 3. DFS of patients under the age of 60 years stratified by cyto-
genetic risk.
Figure 5. DFS of patients $60 years stratified by cytogenetic risk.
Biol Blood Marrow Transplant 15:1306-1313, 2009 1311Autologous HSCTas an Intensive Therapy for Patients with AMLHistorically, allogeneic transplantation has been
reported to result in superior relapse-free survival
(RFS) and OS when compared to autologous BMT.
However, using the CIBMTR data, recent retrospec-
tive analysis showed 5-year OS for patients undergoing
peripheral allogeneic BMT versus peripheral autolo-
gousBMTtobe 59%versus 54%, respectively,without
a statistically significant difference [10]. The median
age of these patients was 36 and 44 years (allogeneic
versus autologous patients), and all were younger than
60 years of age. They did note a statistically significant
difference in TRM in favor of autologous patients ver-
sus allogeneic patients, 8% versus 20%, respectively.
Here we have reported an up-to-date retrospective
analysis from a single institution of patients whoFigure 4. OS of patients under the age of 60 years stratified by cyto-
genetic risk.underwent autologous BMT as a consolidation ther-
apy, using modern methods, for example, peripheral
blood SCT, after achieving complete remission state
followed by high dose chemotherapy. Once stratified
by age, our institutional 5-year OS rates for patients
under age 60 years undergoing APBSCT (65%) are
comparable to those reported by CIBMTR [10]. Fur-
thermore, we report noTRM, considerably lower than
that reported above [10].
In our analysis, several interesting observations
have been noted, which revisits the question of the pre-
cise role that autologous BMT should play. In the past,
randomized studies that compared the autologous
BMT to other modalities such as allogeneic transplan-
tation, intensive chemotherapy, or supportive care have
shown no significant advantage for the autologousFigure 6. OS of patients $60 years stratified by cytogenetic risk.
1312 Biol Blood Marrow Transplant 15:1306-1313, 2009A. S. Jung et al.transplantation group [11]. However, it should be rec-
ognized that most of the reported studies were intent-
to-treat based, which included those patients who
failed to reach the actual intended treatments for what-
ever the reason [10,12].With a large fraction of patients
on these trials failing to receive the various therapeutic
approaches, lack of difference in OS and DFS from
these studies should be interpreted with caution. Al-
though the intent-to-treat analysis may have helped
in reducing potential bias, the power to detect a differ-
ence between autologous and allogeneic transplanta-
tion may be greatly reduced in these circumstances.
In addition, the age range of patients in the previous
large trials [13-18] included pediatric patients and pa-
tients only up to the age of 55 years, significantly differ-
ent from the age group of our cohort.
All the previous large randomized trials trials [13-
18] have also used BM as the primary source of stem
cells rather than mobilized PBSCs, which were used
in our study. Compared with BMT, PBSCT has
been shown to allow for faster hematopoietic recovery
and fewer transfusions [5], which may have contrib-
uted to the absence of TRM that we observed.
In addition, it has been reported that patients who
mobilized the highest numbers of CD341 cells had an
increased risk of relapse and poorer survival, possibly
because of the infusion of malignant cells in the apher-
esis products, but we found no such association in this
series [19,20].
Furthermore, previous randomized trials [13-18]
used an older preparative chemotherapy regimen that
used oral busulfan. The intravenous form of the drug
has been readily available only since late 1990s. Ander-
son et al. [21,22] reported phase I and phase II studies
that showed a more predictable bioavailability of Bu
with the i.v. route, which avoids both the toxicity in
overdosing aswell as the possibility of higher recurrence
when oral Bu was underdosed.
With the use of PBSC mobilization and collection
process in the setting of a modified mobilization regi-
men, along with the use of i.v. Bu in the preparative
chemotherapy regimen, we have observed OS rates in
both the intermediate- and high-risk group of patients,
with age \60, who have undergone APBSCT to be
close to those historically seen in the allogeneic BMT
patients [10].We also observed noTRM.Given the re-
duced risk of GVHD, as well as greater availability of
autologous stem cells, those with intermediate- or
high-risk disease can be offered APBSCT as an option
of consolidation. Although it is not the purpose of this
study to contest the results of the large randomized tri-
als in the past, we believe that given the modern ap-
proaches and observations that we (and the Center
for International Blood and Marrow Transplant Re-
search [CIBMTR]) have made, further studies on
a larger scale are warranted. The outcome of APBSCT
in AML may be improved by the addition ofposttransplant immunomodulation and monitoring
for minimal residual disease.ACKNOWLEDGMENTS
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